A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy
Phase of Trial: Phase III
Latest Information Update: 14 Dec 2018
At a glance
- Drugs Cabozantinib (Primary)
- Indications Thyroid cancer
- Focus Registrational; Therapeutic Use
- Sponsors Exelixis
- 08 Oct 2018 Accoding to a Exelixis media release, Status changed from not yet recruiting to recruiting.
- 27 Sep 2018 Status changed from planning to not yet recruiting.
- 27 Feb 2018 New trial record